跳至主要内容
临床试验/NCT00185328
NCT00185328已完成4 期

A Multi-Center, Open-Label, Non-Comparative Study Investigating the Efficacy and Tolerability of Angeliq® in Postmenopausal Thai Women With Vasomotor Symptoms Over Three 28-Day Treatment Cycles

Bayer0 个研究点目标入组 55 人开始时间: 2005年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Bayer
入组人数
55
主要终点
The relative change in the frequency of hot flushes

研究概览

简要总结

To evaluate the safety, tolerability, and efficacy of Angeliq in Thai post menopausal women with hot flushes and other climacteric symptoms.

详细描述

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Postmenopausal women with hot flushes

排除标准

  • Women with a contraindication for Hormone Replacement Therapy (HRT)

研究组 & 干预措施

Arm 1

Experimental

干预措施: Estradiol/DRSP (Angeliq, BAY86-4891) (Drug)

结局指标

主要结局

The relative change in the frequency of hot flushes

时间窗: At baseline, week 4, 8, 12

次要结局

  • The change in intensity of hot flushes(At baseline, week 4, 8)
  • The relative change in frequency of hot flushes(At baseline, week 4, 8)
  • The proportions of subjects with urogenital symptoms(At baseline, week 4, 8, 12)
  • Bleeding pattern(At baseline, week 4, 8, 12)
  • Adverse events collection(Collection of AE throughout the study period)

研究者

发起方
Bayer
申办方类型
Industry

相似试验